作为单一治疗HER2正常转移性乳腺癌的capecitabine的作用
Anne-Dorthe Mosgaard Knudsen1,2, Mikala Wej Modvig3,4, Marianne Vogsen1,2
1Department of Oncology, Odense University Hospital, Odense, Denmark.
Medical oncology (Northwood, London, England)
|March 28, 2024
概括
在HER2正常转移性乳腺癌 (MBC) 中,单独治疗capecitabine的中位数无进展生存时间为4.3个月. 效率因雌激素受体 (ER) 状态而有显著差异,ER阳性患者的生存时间更长.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性乳腺癌 (MBC) 治疗需要量身定制的策略.
- 人类表皮生长因子受体-2 (HER2) 正常的MBC构成一个独特的子组.
- 皮他是一种口服化疗剂,用于治疗各种癌症.
研究的目的:
- 评估卡佩奇他单一治疗在HER2-正常的MBC患者中的疗效.
- 评估无进展生存率 (PFS) 和整体生存率 (OS) 作为主要和次要终点.
- 根据雌激素受体 (ER) 状态和治疗线路分析治疗结果.
主要方法:
- 对162名HER2-正常的MBC患者进行了回顾性研究,这些患者接受了capecitabine单疗 (2010-2020年).
- 收集的数据包括ER状态,治疗线和生存结果 (PFS和OS).
- 进行了统计分析,以根据ER状态和治疗线路来比较结果.
主要成果:
- 所有患者的中位数PFS为4.3个月,中位数OS为14个月.
- 不同的治疗线路中没有观察到PFS的显著差异.
- 与ER阴性患者相比,ER阳性疾病患者的PFS (5.3个月) 和OS (17.8个月) 中位数明显长 (PFS:2.5个月,OS:7.6个月).
结论:
- 在HER2-正常的MBC中,capecitabine单疗提供了4.3个月的PFS和14个月的OS的中位数.
- 治疗线没有显著影响PFS.
- ER状态是该患者群体中capecitabine疗效的关键预测因素,ER阳性疾病与优异的结果相关.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.9K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
